Compare ETD & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETD | RCKT |
|---|---|---|
| Founded | 1932 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.7M | 534.2M |
| IPO Year | 1996 | N/A |
| Metric | ETD | RCKT |
|---|---|---|
| Price | $22.74 | $3.89 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 14 |
| Target Price | $27.00 | ★ $29.73 |
| AVG Volume (30 Days) | 337.7K | ★ 4.3M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.97% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $766,784,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.73 | $64.28 |
| P/E Ratio | $26.09 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.20 | $2.19 |
| 52 Week High | $31.41 | $8.26 |
| Indicator | ETD | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 56.34 | 49.31 |
| Support Level | $22.48 | $2.95 |
| Resistance Level | $25.12 | $4.08 |
| Average True Range (ATR) | 0.53 | 0.20 |
| MACD | 0.11 | 0.04 |
| Stochastic Oscillator | 83.17 | 72.19 |
Ethan Allen Interiors Inc through its subsidiaries, operates as an interior design company, and a manufacturer and retailer in the home furnishings marketplace. Its product offerings include fabric chairs, beds, wallpapers, desks, and dining tables among others. The company's reportable segments are; Wholesale and Retail. The Wholesale segment is principally involved in the development of the Ethan Allen brand and encompasses all aspects of design, manufacturing, sourcing, marketing, sale, and distribution of home furnishings and accents. The Retail segment which generates maximum revenue, sells home furnishings and accents to clients through company-operated design centers. Geographically, it derives key revenue from the United States and the rest from other regions.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.